Rexahn pharmaceuticals, inc. (RNN)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:

1,150

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

-

0

0

-

-

-

0

0

0

18

Expenses:
General and administrative

1,256

1,553

1,149

1,340

1,695

2,236

1,795

1,568

1,827

1,634

1,574

1,739

1,690

1,834

1,418

1,675

1,395

1,450

1,554

1,584

1,524

1,634

1,316

1,807

1,494

1,724

932

857

1,210

642

600

742

728

736

774

927

1,109

1,561

1,805

Research and development

456

454

1,131

1,648

2,242

2,729

2,887

3,432

4,058

3,263

2,644

2,544

2,262

2,084

2,298

2,237

3,468

2,916

3,103

3,235

2,893

2,218

1,824

1,701

1,271

994

781

925

552

265

1,066

1,018

1,042

1,485

2,372

5,417

2,717

671

1,328

Patent fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

100

121

136

128

122

77

102

171

198

103

72

123

62

Depreciation and amortization

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9

9

9

10

10

10

10

10

10

10

14

11

11

Total Expenses

1,712

2,008

2,280

2,988

3,937

4,966

4,683

5,001

5,885

4,898

4,219

4,283

3,953

3,919

3,717

3,912

4,863

4,367

4,658

4,819

4,417

3,852

3,141

3,508

2,766

2,332

1,823

1,913

1,909

1,046

1,799

1,848

1,884

2,404

3,355

6,458

3,913

2,367

3,207

Loss from Operations

-562

-2,008

-2,280

-2,988

-3,937

-4,966

-4,683

-5,001

-5,885

-4,898

-4,219

-4,283

-3,953

-3,919

-3,717

-3,912

-4,863

-4,367

-4,658

-4,819

-4,417

-3,852

-3,141

-3,508

-2,766

-2,332

-1,823

-1,913

-1,909

-1,046

-1,799

-1,848

-1,884

-2,404

-3,355

-6,458

-3,913

-2,367

-3,189

Other Income
Realized loss on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-3

0

0

0

Interest income

34

57

78

96

81

55

55

67

75

71

60

42

31

34

26

28

28

21

23

27

30

28

34

38

32

14

13

11

10

3

6

4

6

8

19

38

42

49

26

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Other income

-

-

-

-

-

0

0

0

368

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

56

Unrealized (loss) gain on fair value of warrants

58

-82

-242

-427

-1,513

-1,793

710

-1,095

-3,366

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized (loss) gain on fair value of warrants

-

-

-

-

-

-

-

-

-

-

3,120

5,521

-17,689

1,588

967

2,118

855

-

608

1,558

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized gain on fair value of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-115

-

-1,201

-3,665

11,660

310

217

1,206

-368

-1,319

1,195

-802

261

-2,784

-1,866

-594

467

-2,536

310

Unrealized gain on fair value of put feature on common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Financing expense

-

-

-

-

-

-

-

-

-

-

-

333

-

0

143

0

169

-

-

-

-

0

0

0

206

-

112

-

-

-

-

-

-

0

0

0

97

0

180

Beneficial conversion feature

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Total Other (Loss) Income

-23

139

321

524

1,594

1,849

-654

1,163

3,810

1,305

3,181

5,230

-17,657

3,393

850

2,146

714

1,515

632

1,585

145

1,642

1,236

3,703

-11,834

-387

-317

-1,195

378

991

-1,189

806

-255

2,793

1,885

629

-522

2,586

-408

Net Loss Before Provision for Income Taxes

-586

-1,868

-1,959

-2,464

-2,342

-3,116

-5,338

-3,838

-2,074

-3,592

-1,038

947

-21,611

-525

-2,866

-1,765

-4,149

-2,852

-4,026

-3,234

-4,271

-2,210

-1,905

194

-14,600

-2,719

-2,140

-3,108

-1,530

-55

-2,989

-1,042

-2,139

389

-1,469

-5,828

-4,436

218

-3,597

Provision for Income Taxes

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

-

0

0

-

-

-

0

0

0

0

Net Loss

-586

-1,868

-1,959

-2,464

-2,342

-3,116

-5,338

-3,838

-2,074

-3,592

-1,038

947

-21,611

-525

-2,866

-1,765

-4,149

-2,852

-4,026

-3,234

-4,271

-2,210

-1,905

194

-14,600

-2,719

-2,140

-3,108

-1,530

-55

-2,989

-1,042

-2,139

389

-1,469

-5,828

-4,436

218

-3,597

Net Income (Loss) per share, basic

-

-

-

-

-

-

-

-

-

-

-

0.04

-

-

-

-0.08

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) per share, diluted

-

-

-

-

-

-

-

-

-

-

-

0.03

-

-

-

-0.08

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average number of shares outstanding, basic

-

-

-

-

-

-

-

-

-

-

-

26,001

-

-

-

21,318

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average number of shares outstanding, diluted

-

-

-

-

-

-

-

-

-

-

-

28,265

-

-

-

21,318

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share, basic and diluted

-0.15

-0.46

-0.49

-0.61

-0.62

-0.99

-2.02

-1.45

-0.79

-

-0.04

-

-0.91

-

-0.13

-

-0.02

-0.73

-0.02

-0.02

-0.02

-0.01

-0.01

0.00

-0.09

-0.01

-0.02

-0.03

-0.01

0.00

-0.03

-0.01

-0.02

0.01

-0.02

-0.06

-0.05

0.00

-0.05

Weighted average number of shares outstanding, basic and diluted

4,019

4,022

4,019

4,019

3,779

3,031

2,641

2,640

2,639

-

28,459

-

23,851

-

21,644

-

202,586

-466,693

180,701

179,849

179,097

178,365

178,219

177,729

170,112

145,154

130,466

119,547

119,428

102,515

95,345

95,345

95,345

95,464

95,240

95,237

86,251

-

-

Weighted Average number of shares outstanding, basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

83,063

74,247